Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Disease Progression × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 37 Brain Neoplasms 16 Astrocytoma 16 Central Nervous System Neoplasms 9 Oligodendroglioma 8 Gliosarcoma 8 Melanoma 7 Glioma 7 Neoplasms 5 Recurrence 4 Neoplasm Metastasis 3 Diffuse Intrinsic Pontine Glioma 2 Choroid Plexus Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Sarcoma, Ewing 1 Sarcoma 1 Rhabdoid Tumor 1 Rare Diseases 1 Optic Nerve Glioma 1 Neurotoxicity Syndromes 1 Neuroendocrine Tumors 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasms, Neuroepithelial 1 Neoplasms, Connective and Soft Tissue 1 Neoplasms, Connective Tissue 1 Neoplasms, Bone Tissue 1 Neoplasms by Histologic Type 1 Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1 Lymphoma, Follicular 1

Interventions

Lenalidomide 3 capivasertib 2 Bortezomib 2 tivozanib 1 Zoledronic Acid 1 Vitamin D 1 Temozolomide 1 Radiotherapy 1 Nivolumab 1 Fulvestrant 1 Etoposide 1 Dexamethasone 1 Cisplatin 1 Carboplatin 1 Calcium Dobesilate 1 Calcium 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02761070 2023-03-08

RE-GEND

Kyorin University

Phase 3 Unknown

Glioblastoma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡